Risk and Prediction of Sudden Cardiac Death and Ventricular Arrhythmias for Patients with Atrial Fibrillation – A Nationwide Cohort Study

Tze-Fan Chao\textsuperscript{1,2,*}, Chia-Jen Liu\textsuperscript{3,4,*}, Ta-Chuan Tuan\textsuperscript{1,2,#}, Su-Jung Chen\textsuperscript{4,5}, Tzeng-Ji Chen\textsuperscript{6}, Gregory Y. H. Lip\textsuperscript{7,8} & Shih-Ann Chen\textsuperscript{1,2}

Sudden cardiac death (SCD) is the most devastating manifestation of ventricular arrhythmias (VAs), and is the leading cause of mortality amongst atrial fibrillation (AF) patients. The goal of the present study was to investigate the incidence of SCD/VAs amongst patients with and without AF. We also aimed to identify important risk factors of SCD/VAs among AF patients. Using the "National Health Insurance Research Database" in Taiwan, a total of 352,656 AF and 352,656 non-AF patients without antecedent SCD/VAs were identified. The annual risk of SCD/VAs was higher in AF than non-AF groups (0.97\% versus 0.47\%) with an adjusted hazard ratio (HR) of 1.64. The increased risk of SCD/VAs in AF patients was consistently observed in different age strata, various comorbidities and patients without use of class I/III anti-arrhythmic drugs or digoxin. Among AF patients, age ≥75 years, congestive heart failure, hypertension, diabetes mellitus, previous stroke/transient ischemic attack, vascular diseases, chronic kidney disease and chronic obstructive pulmonary disease were important risk factors for SCD/VAs. In conclusion, the risk of SCD/VAs amongst AF patients was 1.64-fold higher compared to non-AF patients, which was associated with the number of clinical risk factors associated with the particular AF patient.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is projected to continuously increase over the next few decades\textsuperscript{1,2}. AF not only increases the risk of stroke, but also increases the risk of death by 1.5 fold in males and 1.9-fold in females in Framingham Heart Study\textsuperscript{3}. Sudden cardiac death (SCD), the most devastating manifestation of ventricular arrhythmias (VAs), including ventricular tachycardia and ventricular fibrillation, was the leading cause of mortality (around 22\%) among AF patients enrolled in the Randomized Evaluation of Long-Term Anti-coagulation Therapy (RE-LY) trial\textsuperscript{4}. A recent study analyzing the data from the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Study (CHS) cohorts has demonstrated that the risk of SCD was higher in AF patients (n = 2,352) than non-AF patients (n = 18,566) with a hazard ratio (HR) of 2.47 after the adjustment for multiple confounders\textsuperscript{5}.

However, the relationship between the risk of SCD/VAs and AF has not been well studied in a "non-selected" nationwide cohort. Furthermore, the incidence of SCD/VAs stratified by age, gender and its predictors remains unclear, especially in an Asian cohort of AF patients. The goal of the present study was to investigate the incidence...
of SCD/VAs of AF patients, and compare their risk to non-AF subjects in relation to gender and age strata. Second, we also aimed to identify important risk factors for SCD/VAs among AF patients.

Methods
Nearly all Taiwanese residents were covered by the National Health Insurance (NHI) system, which offers comprehensive medical care coverage. The "National Health Insurance Research Database (NHIRD)" which included detailed information about health care of more than 23 million enrollees was released by the Taiwan government for the research purpose. The large sample size of this database provides a good opportunity to study the incidence and risk factors for SCD/VAs among AF patients.

Study cohort. The study design of the present study is similar to our previous studies using this dataset6–10. Over the 16-year period, 1996 to 2011, 354,649 newly-diagnosed AF patients aged ≥20 years were identified.
from the NHIRD as the study population. AF was diagnosed using the International Classification of Diseases (ICD), Ninth Revision, Clinical Modification (ICD-9-CM) codes (427.31). Patients were diagnosed to have AF only when it was a discharge diagnosis or was confirmed on at least two occasions in the outpatient department. The diagnostic accuracy of AF with this definition in Taiwan NHIRD has been validated in previous studies. Among the study population, we excluded patients who have experienced and survived from previous episodes of SCD/VAs. Finally, a total of 352,656 AF patients without antecedent SCD/VAs were identified as the study population. For each AF patient, 1 age- and gender-matched control without AF and history of SCD/VAs was selected to constitute the control group (n = 352,656). Figure 1 shows the flowchart of the enrollment of the study cohort.

The comorbidities of each subject were diagnosed according to the ICD-9-CM codes registered by clinical physicians responsible for the care of the patient. Previous studies have validated the diagnostic accuracies of important systemic diseases in Taiwan NHIRD, including myocardial infarction, congestive heart failure, diabetes mellitus, ischemic stroke, hyperlipidemia, chronic obstructive pulmonary disease (COPD) and hypertension. Information about the degree of urbanization (urban, suburban or rural) of each patient was available in Taiwan NHIRD based on the townships where the patients lived. The stratifications of townships were based on the township population density (people/km²), population ratio of people with college or above educational
levels, population ratio of elder people over 65 years old, population ratio of people of agriculture workers and the number of physicians per 100,000 people (http://ntur.lib.ntu.edu.tw/bitstream/246246/176519/1/5.pdf).

Clinical endpoints. The clinical endpoints were defined as hospitalization or emergency department visit with the principal diagnosis of SCD (ICD-9-CM code 427.5, 798.1, or 798.2) and VAs (including ventricular tachycardia [ICD-9-CM code 427.1] and ventricular fibrillation and flutter [ICD-9-CM code 427.4, 427.41, or 427.42])\(^{17,18}\). During the mean follow up of 4.87 ± 3.97 years, there were 14,221 and 9,360 patients who experienced SCD/VAs in the AF and non-AF groups, respectively (Fig. 1).

Statistical analysis. Continuous variables were summarized using mean value and standard deviation, and categorical variables were summarized using frequency and percentage. The differences between continuous variables and nominal variables were assessed with unpaired two-tailed t-test and chi-squared test, respectively. Incidence rates of SCD/VAs were calculated from dividing the number of event by person-time at risk. The cumulative incidence curve of SCD/VAs was plotted via the Kaplan-Meier method, with statistical significance examined by the log-rank test. Independent predictors for the risk of SCD/VAs were assessed using a multivariable Cox regression analysis. All statistical significances were set at a \( p < 0.05 \).
The study was approved by the Institutional Review Board (IRB) at Taipei Veterans General Hospital, Taipei, Taiwan. Since the patients’ original identification numbers have been encrypted to protect their privacy in NHIRD, the IRB agreed that the inform consent of the patient could be waived.

Results
Baseline characteristics of AF and non-AF patients are shown in Supplemental Table 1. Age and gender were matched between the 2 groups. AF patients had more comorbidities, except for vascular disease and end-stage renal disease (ESRD).

During the follow up of 3,437,771 person-years, 23,581 patients suffered from SCD/V As (14,221 in AF and 9,360 in non-AF groups). Baseline characteristics of these patients are shown in Supplemental Table 2. The annual risk of SCD/V As was higher in the AF group compared to the non-AF group (0.97% versus 0.47%). AF patients were associated with a higher risk of SCD/V As than non-AF patients during the follow up period, with an adjusted hazard ratio (HR) of 1.64 (95% CI 1.60–1.69) (Fig. 2). AF patients were still associated with an increased risk of SCD/V As with an adjusted HR of 1.72 (95% CI 1.67–1.77, \( p < 0.001 \)) after considering age, sex and important comorbidities in the competing-risk model.

In subgroup analyses, AF was consistently associated with a higher risk of SCD/V As compared to non-AF patients in different subgroups of patients (Fig. 3). The associated risk was particularly higher amongst those age \(< 75\) \( (p_{\text{int}} < 0.001) \), ESRD \( (p_{\text{int}} < 0.001) \), malignancy \( (p_{\text{int}} = 0.009) \), autoimmune disease \( (p_{\text{int}} = 0.011) \), liver cirrhosis \( (p_{\text{int}} = 0.025) \) and those without hypertension \( (p_{\text{int}} < 0.001) \), previous stroke/transient ischemic attack \( (p_{\text{int}} < 0.001) \), and vascular diseases \( (p_{\text{int}} < 0.001) \). The risk of SCD/V As was still higher among AF patients without use of class I/III anti-arrhythmic drugs (AADs) and digoxin \( (n = 252,843) \) compared to non-AF patients with an adjusted HR of 1.66 (95% CI 1.60–1.72).

Risk of SCD/VAs in AF and non-AF patients stratified by age and gender. Figure 4 shows the annual risk of SCD/V As of AF and non-AF patients stratified by age for all \( (\text{Fig. 4A}) \), male \( (\text{Fig. 4B}) \) and female \( (\text{Fig. 4C}) \) patients. The risk of SCD/V As continuously increased with age, and was consistently higher in AF patients in each age stratum irrespective of gender. Figure 5 demonstrates the risk of SCD/V As of AF compared to non-AF patients represented by HRs. AF significantly increased the risk of SCD/V As in all age groups irrespective of gender, especially amongst younger patients.

Propensity-matched analysis. Because AF and non-AF patients have different baseline characteristics, we performed a propensity score–matched analysis, in which we calculated a propensity score for the likelihood of AF by multivariate logistic regression analysis, conditional on the baseline covariates listed in Supplemental Table 1. After that, we matched each AF patient to a non-AF patient on the basis of propensity score \( \pm 0.01 \). Baseline characteristics of the AF and non-AF patients after the propensity match were shown in Supplemental Table 3. The propensity scores were similar between 2 groups \( (0.53 \text{ versus } 0.53, \ p = 0.175) \). The annual risk of SCD/V As was higher in the AF group compared to the non-AF group \( (0.96\% \text{ versus } 0.45\%) \). AF patients were associated with a higher risk of SCD/V As than non-AF patients with a HR of 1.52 (95% CI 1.49–1.57).

Risk factors for SCD/VAs among AF patients. Among 352,656 AF patients with a follow-up of 4.15 ± 3.78 years, 14,221 patients \( (4.2\%) \) experienced SCD/V As. The baseline characteristics of AF patients with or without SCD/V As are shown in Table 1. AF patients who suffered from SCD/V As were older with a higher...
prevalence rate of comorbidities, except for malignancy, autoimmune diseases and liver cirrhosis, compared to patients without SCD/V As.

Among the AF patients, age $\geq 75$ years, congestive heart failure, hypertension, diabetes mellitus, previous stroke/TIA, vascular diseases, chronic kidney disease (CKD), including ESRD and non-ESRD CKD, and COPD were identified to be independent risk factors for SCD/V As (Table 2). The risk of SCD/V As was proportional to the number of risk factors attributable to a patient (Fig. 6A), where the HR of SCD/V As increased from 1.68 (95% CI 1.54–1.84) for 1 risk factor rising to 8.75 (95% CI 6.92–11.08) for patients with 8 risk factors, in comparison to those without any risk factors (Supplemental Table 4).

With an increase in the number of risk factors in AF patients, the cumulative event rate correspondingly increased (Fig. 6A and B). Even for AF patients without any significant clinical risk factors, the annual risk of SCD/V As was around 0.3%, which was still higher than non-AF patients with an adjusted HR of 2.03 (95% CI 1.85–2.23, p value $< 0.001$).

Discussion
In this large-scale nationwide cohort study, we our principal findings are as follows: (1) The annual risk of SCD/V As of AF patients was around 0.97%, which was 1.64-fold higher than non-AF patients; (2) The increased risk of SCD/V As in AF patients was consistently observed in different age strata, various comorbidities and patients without use of class I/III AADs or digoxin; and (3) The individual risk of SCD/V As for AF patients can be estimated according to the number of clinical risk factors including age $\geq 75$ years, congestive heart failure, hypertension, diabetes mellitus, previous stroke/TIA, vascular diseases, CKD and COPD.

| Variables                          | With SCD/VAs (n = 14,221) | Without SCD/VAs (n = 338,435) | P value |
|-----------------------------------|---------------------------|-------------------------------|---------|
| Age, years; mean value (SD)       | 72.4 (12.2)               | 71.3 (13.1)                  | $< 0.001$ |
| Age $\geq 75$ years, n (%)        | 7,038 (49.5)              | 157,069 (46.4)               | $< 0.001$ |
| Male gender, n (%)                | 8,000 (56.3)              | 187,357 (55.4)               | 0.035   |
| Comorbidities, n (%)              |                           |                               |         |
| Congestive heart failure          | 7,291 (51.3)              | 136,621 (40.4)               | $< 0.001$ |
| Hypertension                      | 10,121 (71.2)             | 231,210 (68.3)               | $< 0.001$ |
| Diabetes mellitus                 | 4,619 (32.5)              | 96,065 (28.4)                | $< 0.001$ |
| Previous stroke/TIA               | 5,175 (36.4)              | 117,707 (34.8)               | $< 0.001$ |
| Vascular diseases                 | 3,421 (24.1)              | 76,125 (22.5)                | $< 0.001$ |
| Non-ESRD CKD                      | 2,426 (17.1)              | 51,157 (15.1)                | $< 0.001$ |
| ESRD                              | 495 (3.5)                 | 7,261 (2.2)                  | $< 0.001$ |
| COPD                              | 5,368 (37.8)              | 119,690 (35.4)               | $< 0.001$ |
| Malignancy                        | 563 (4.0)                 | 18,857 (5.6)                 | $< 0.001$ |
| Autoimmune diseases               | 700 (4.9)                 | 18,766 (5.5)                 | 0.001   |
| Liver cirrhosis                   | 428 (3.0)                 | 11,356 (3.4)                 | 0.025   |
| Medications, n (%)                |                           |                               |         |
| Aspirin                           | 4,513 (31.7)              | 102,647 (30.3)               | $< 0.001$ |
| Clopidogrel                       | 679 (4.8)                 | 13,882 (4.1)                 | $< 0.001$ |
| Warfarin                          | 1,664 (11.7)              | 40,222 (11.9)                | 0.507   |
| Beta-blockers                     | 2,234 (15.7)              | 60,050 (17.7)                | $< 0.001$ |
| CCBs                              | 1,374 (9.7)               | 30,267 (8.9)                 | 0.003   |
| Digoxin                           | 3,205 (22.5)              | 57,915 (17.1)                | $< 0.001$ |
| Class I AADs                      | 427 (3.0)                 | 12,388 (3.7)                 | $< 0.001$ |
| Class III AADs                    | 1,359 (9.6)               | 29,650 (8.8)                 | 0.001   |
| ACEIs/ARBs                        | 4,344 (30.6)              | 97,110 (28.7)                | $< 0.001$ |
| Statins                           | 712 (5.0)                 | 13,948 (4.1)                 | $< 0.001$ |
| Degree of urbanization, n (%)     |                           |                               |         |
| Urban                             | 7,498 (52.7)              | 174,095 (51.4)               | 0.004   |
| Suburban                          | 4,658 (32.8)              | 112,536 (33.3)               |         |
| Rural                             | 2,065 (14.5)              | 51,804 (15.3)                |         |
| Income level, n (%)               |                           |                               |         |
| Low                               | 7,748 (54.5)              | 181,336 (53.6)               | 0.031   |
| Median                            | 4,696 (33.0)              | 112,537 (33.3)               |         |
| High                              | 1,777 (12.5)              | 44,562 (13.2)                |         |

Table 1. Baseline characteristics of AF patients with or without SCD/VAs. AADs = anti-arrhythmic drugs; ACEI = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin II-receptor blocker; CCBs = calcium channel blockers; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; ESRD = end-stage renal disease; SD = standard deviation; TIA = transient ischemic attack.
Evidence suggesting that AF may increase the risk of VAs comes from recipients of implantable cardioverter-defibrillators (ICDs). For example, in one prospective study which enrolled 250 patients receiving ICD for secondary prevention, AF patients experienced appropriate device therapy for recurrent VAs 1.8 fold more commonly, compared with non-AF patients. An analysis of device-stored electrograms revealed a higher incidence of short-long-short cycles preceding VAs in AF compared to non-AF patients (55% vs 31%, p = 0.01). The relationship between new-onset AF and risk of SCD was also been evaluated in 8,831 hypertensive patients with electrocardiographic left ventricular hypertrophy without history of AF enrolled in the Losartan Intervention For Endpoint reduction (LIFE) study. After adjustment for potential confounders, AF remained as an important risk factor of SCD with a HR 3.13 (95% CI 1.87–5.24). In a recent study which analyzed data from ARIC study and CHS, a significant link between AF and SCD was been demonstrated among community-dwelling individuals.

Although the association between AF and SCD/VAs has been reported, the risk of SCD/VAs for AF patients stratified by age and gender remains unknown due to the selected patient population in previous studies with a small sample sizes. In the present study, the mean age of AF population was 74 years which was similar to that of patients enrolled in CHS (73 years), and the annual risks of SCD/VAs were also similar (0.97% versus 1.2%). Of particular importance, the present study is the first large-scale nationwide cohort study providing the epidemiological data regarding the risk of SCD/VAs, specifically among Asian AF patients with data for gender and each age strata. For both AF and non-AF patients, the risk of SCD/VAs continuously increased with age, and the risk
of SCD/VAs of AF patients age <40 years was ten-fold higher than non-AF controls. The AF-associated increase in risk of SCD/VAs was higher for patients age <75 years than those aged ≥75 years (HR = 1.93 versus 1.44, p\textsubscript{int} < 0.001, Fig. 3). Although the HRs of SCD/VAs in AF were attenuated among patients aged ≥75 years, the risk still remained statistically significant (HR = 1.44, 95% CI = 1.38–1.50, Fig. 3).

While we have demonstrated that AF patients were associated with an increased risk of SCD/VAs, the detailed mechanisms behind the link were unclear. It is possible that the association between AF and SCD is mediated by shared risk factors such as heart failure and vascular diseases. However, AF remained significantly associated with SCD/VAs after the adjustments for potential confounders using multivariate Cox regression, propensity-matched and competing-risk analyses in the present study. Besides, AF-associated increases in risk of SCD/VAs are statistically similar for patients with or without heart failure with HRs of 1.54 and 1.63, respectively (p\textsubscript{int} = 0.432). In the previous analysis of ARIC cohort, the risk of SCD was still higher for AF patients after the adjustment for fractional shortening of left ventricle measured by 2-dimensional echocardiogram. These results may suggest that the association between AF and SCD/VAs is not simply mediated by left ventricular dysfunction and could not be completely explained by shared risk factors. Indeed, a rapid ventricular rate during an atrial tachyarrhythmia could reduce ventricular refractoriness and promote VAs\textsuperscript{21}. In addition, the irregular rhythm of AF may reduce ventricular refractoriness and promote VAs\textsuperscript{21}. Therefore, AF itself may facilitate the induction of VAs and cause SCD\textsuperscript{23}.

**Clinical implications.** Although the risk of SCD/VAs is higher in AF than non-AF subjects, the risk factors accentuating this risk and how to estimate the individual risk of SCD/VAs for AF patients were not been well investigated. In the present study, several important clinical factors associated with the occurrence of SCD/VAs were identified. We found that the incidence of SCD/VAs increased as more risk factors were present, increasing to 3.2%/year for AF patients with all 8 risk factors, constituting an 8.75-fold increased risk for the development of SCD/VAs in comparison with patients without any risk factors. The annual risk of SCD/VAs for each AF patient could be easily estimated based on the number of the risk factors that the patient has. Thus, clinicians should pay attention to the potential risk of SCD/VAs for AF patients with multiple risk factors, especially when patients experience episodes of near fainting or syncope. Whether more aggressive treatment and better control of blood pressure, hyperglycemia and congestive heart failure could decrease the risk of SCD/VAs deserves further study.

**Limitations.** First, since AF patients had more comorbidities than non-AF patients, whether AF was the direct cause responsible for the higher risk of SCD/VAs remains unknown. Although we have tried to adjust for age, sex and important comorbidities in the competing-risk model, we were not able to exclude the possibility that some other confounders were not recognized and may therefore confound the analysis. Second, data on the subtypes of AF were not available, and therefore we can not investigate whether the risk of SCD/VAs were different for paroxysmal and non-paroxysmal AF patients. Third, the diagnosis of SCD/VAs was based on the diagnostic codes registered in the database, and the real incidence of SCD/VAs is likely to be underestimated. Besides, we were not able to further clarify the SCD event as being witnessed or witnessed. Fourth, age is a continuous variable which was associated with an increased risk of SCD/VAs, and the setting of the cutoff value (75 years) is just for the convenience to assess patient’s risk in the daily practice. Indeed, age 65–74 years was also associated with an increased risk of SCD/VAs with an adjusted HR of 1.27 (95% CI = 1.21–1.33) compared to patients aged <65 years. However, the HR of SCD/VAs associated with an age ≥75 years (1.63, 95% CI = 1.57–1.69) was higher than for patients age <75 years (1.44, 95% CI = 1.38–1.50, Fig. 3).


d| 
| --- | --- | --- | --- | --- |
| Variables | Univariate analysis | Multivariate analysis* |
| | HR (95% CI) | P value | HR (95% CI) | P value |
| Age ≥75 years | 1.97 (1.91–2.04) | <0.001 | 1.63 (1.57–1.69) | <0.001 |
| Male gender | 1.02 (0.99–1.05) | 0.251 |  |

**Table 2. Clinical predictors of SCD/VAs among AF patients.** Variables with p values < 0.05 in the univariate analyses were included in the multivariate model which was adjusted for the use of medications listed in Table 1, degree of urbanization and income level. AF = atrial fibrillation; CI = confidence interval; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; ESRD = end-stage renal disease; HR = hazard ratio; SCD = sudden cardiac death; TIA = transient ischemic attack; VAs = ventricular arrhythmias.
than that of age 65–74 years. Last, the present study only enrolled Asian (ie. Taiwanese) patients, and whether the results can be extrapolated to other populations remains uncertain.

Conclusion
In this nationwide cohort study, the risk of SCD/VAs amongst AF patients was 1.64-fold higher compared to non-AF patients. The individual risk of SCD/VAs can be associated with the number of clinical risk factors associated with the particular AF patient.

References
1. Miyasaka, Y. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* **114**, 119–125 (2006).
2. Tse, H. F. et al. Stroke prevention in atrial fibrillation—an Asian stroke perspective. *Heart Rhythm* **10**, 1082–1088 (2013).
3. Benjamin, E. J. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation* **98**, 946–952 (1998).
4. Marjon, E. et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term antiarrhythmic therapy study. *Circulation* **128**, 2192–2202 (2013).
5. Chen, L. Y. et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. *JAMA internal medicine* **173**, 29–35 (2013).
6. Chao, T. F. et al. Acute myocardial infarction in patients with atrial fibrillation—a nationwide cohort study. *Heart Rhythm* **11**, 1941–1947 (2014).
7. Chao, T. F. et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. *Can J Cardiol* **30**, 1190–1195 (2014).
8. Chao, T. F. et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation. *J Am Coll Cardiol* **64**, 1658–1665 (2014).
9. Chao, T. F. et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? *J Am Coll Cardiol* **65**, 635–642 (2015).
10. Liao, J. N. et al. Risk and prediction of dementia in patients with atrial fibrillation - A nationwide population-based cohort study. *Int J Cardiol* **199**, 25–30 (2015).
11. Lin, L. J. et al. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation—a nationwide descriptive study in Taiwan. *Clin Ther* **30**, 1726–1736 (2008).
12. Chang, C. H. et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. *Atherosclerosis* **232**, 224–230 (2014).
13. Lin, C. C., Lai, M. S., Syu, C. Y., Chang, S. C. & Tseng, F. Y. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. *Journal of the Formosan Medical Association* **104**, 157–163 (2005).
14. Cheng, C. L., Kao, Y. H., Lin, S. J., Lee, C. H. & Lai, M. I. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. *Pharmacoeconomic Drug Saf* **20**, 236–242 (2011).
15. Hsieh, C. Y., Chen, C. H., Li, C. Y. & Lai, M. L. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. *Journal of the Formosan Medical Association* **114**, 254–259 (2015).
16. Perk, C. L. et al. Risk of depressive disorder following non-alcoholic cirrhosis: a nationwide population-based study. *PloS one* **9**, e8721 (2014).
17. Shih, C. J. et al. Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: a nationwide population-based study. *Circulation* **130**, 1684–1691 (2014).
18. Wu, C. S., Tsai, Y. T. & Tsai, H. J. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nationwide case-crossover study. *Journal of the American Heart Association* **4**, e001568, doi: 10.1161/JAHA.114.001568 (2015).
19. Gronenfeld, G. C., Mauss, O., Li, Y. G., Klingenhoven, T. & Hohnloser, S. H. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. *J Cardiovasc Electrophysiol* **11**, 1208–1214 (2000).
20. Olin, P. M. et al. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. *Circ Arrhythm Electrophysiol* **6**, 243–251 (2013).
21. Denes, P., Wu, D., Dhingra, R., Pietras, R. J. & Rosen, K. M. The effects of cycle length on cardiac refractory periods in man. *Circulation* **49**, 32–41 (1974).
22. Denker, S., Lehmann, M., Mahmoud, R., Gilbert, C. & Akhtar, M. Facilitation of ventricular tachycardia induction with abrupt changes in ventricular cycle length. *Am J Cardiol* **53**, 508–515 (1984).
23. Chen, L. Y., Benditt, D. G. & Alonso, A. Atrial fibrillation and its association with sudden cardiac death. *Circ J* **78**, 2588–2593 (2014).

Acknowledgements
This work was supported in part by grants from the Ministry of Science and Technology (MOST 104-2314-B-075-024-MY3), and Taipei Veterans General Hospital (V101D-001-2, V102B-025, V103B-018, and V105B-023).

Author Contributions
The specific contributions made to this article by the listed authors are as follows: T.-F.C. and C.-J.L. drafted the manuscript and plotted the figures. C.-J.L. performed data analysis. T.-F.C., S.-J.C., T.-J.C. and S.-A.C. designed the study. T.-C.T. and G.Y.H.L. revised the manuscript and took responsibility for the interpretation of the results. All authors have reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing Interests: The authors declare no competing financial interests.

How to cite this article: Chao, T.-F. et al. Risk and Prediction of Sudden Cardiac Death and Ventricular Arrhythmias for Patients with Atrial Fibrillation – A Nationwide Cohort Study. *Sci. Rep.* **7**, 46445; doi: 10.1038/srep46445 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
